Transaction · 0000905148-25-000725

Blume-Jensen Peter

Blume-Jensen Peter, PRES, reported a transaction classified as withholding at Acrivon Therapeutics, Inc. involving 37152.000000 shares for an estimated $201363.84. Reported holdings after the transaction were 2305685.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

withholdingSEC transaction code FPRES
ACRVAcrivon Therapeutics, Inc.
Filing timeFeb 19
Trade dateFeb 14, 2025
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
…
Pre-filing
…
Returns since
…

ACRV price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
ACRV since 2025-02-19Filed 562 days ago · 30 days of pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
withholding
Code F
Identifier
0000905148-25-000725
Common Stock
Transaction date
Feb 14, 2025
Filed Feb 19, 2025, 09:52 PM · 5d delay
Shares
37.1k sh
$542 per share
Estimated value
-$20.1M
Computed from shares × price
Holdings after
2.30M sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Direct Ownership
-16score
Filing-only score

-16

Compact filing score computed from stored Form 4 facts. Version v1.

Mixed or weak signal

This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

President and CEO

Officer YesDirector Yes10% NoOther No
Footnotes & amended
  1. F1

    Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

  2. F2

    These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of h…

  3. F3

    These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of…

Original filing · 0000905148-25-000725
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

ACRV